Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide
Aims The aim of this study was to characterize the population pharmacokinetics of AZD8233,
an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.
O Clewe, D Rekić, AL Quartino, B Carlsson… - British Journal of …, 2024 - europepmc.org
The aim of this study was to characterize the population pharmacokinetics of AZD8233, an
antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide
O Clewe, D Rekić, AL Quartino… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Aims The aim of this study was to characterize the population pharmacokinetics of AZD8233,
an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce hepatocyte …
[PDF][PDF] Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide
M Higashimori, L Wernevik, A Hofherr… - 2024 - researchgate.net
Aims: The aim of this study was to characterize the population pharmacokinetics of
AZD8233, an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce …
AZD8233, an antisense oligonucleotide (ASO) that targets the PCSK9 transcript to reduce …